The BCL6 protein facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage ...

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress. Arvinas Inc. Fri, Jun 13, 2025, 7:00 AM 6 min read.

Arvinas to present preclinical data on ARV-393, a BCL6 degrader, at the EHA meeting in Milan, June 2025. Quiver AI Summary. Arvinas, Inc. announced that it will present new preclinical data on its ...

PRINCETON, N.J., June 12, 2025--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 ...

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress Arvinas Inc. - GlobeNewswire - Fri Jun 13, 6:00AM CDT ...

--Arvinas, Inc., a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical data for ARV-393 will be ...

– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic ...

BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) ...

Arvinas Presents Preclinical Data For PROTAC BCL6 Degrader, ARV-393, At The European Hematology Association 2025 Congress. Date. 2025-06-13 07:16:07. Share on Facebook; Tweet on Twitter ...

BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) model of nodal ...